Generic Oxlumo Availability
Last updated on May 7, 2025.
Oxlumo is a brand name of lumasiran, approved by the FDA in the following formulation(s):
OXLUMO (lumasiran sodium - solution;subcutaneous)
-
Manufacturer: ALNYLAM PHARMS INC
Approval date: November 23, 2020
Strength(s): EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML) [RLD]
Is there a generic version of Oxlumo available?
No. There is currently no therapeutically equivalent version of Oxlumo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oxlumo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Glycoconjugates of RNA interference agents
Patent 10,131,907
Issued: November 20, 2018
Inventor(s): Forst Andrea & Hadwiger Philipp & Vornlocher Hans-Peter
Assignee(s): ALNYLAM PHARMACEUTICALS, INC.The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
Patent expiration dates:
- August 24, 2028✓✓✓
- August 24, 2028
-
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent 10,435,692
Issued: October 8, 2019
Inventor(s): Brown Bob D. & Dudek Henryk T.
Assignee(s): Dicerna Pharmaceuticals, Inc.This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Patent expiration dates:
- December 26, 2034✓
- December 26, 2034
-
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent 10,465,195
Issued: November 5, 2019
Inventor(s): Brown Bob D. & Dudek Henryk T.
Assignee(s): Dicerna Pharmaceuticals, Inc.This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Patent expiration dates:
- December 26, 2034✓✓✓
- December 26, 2034
-
Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Patent 10,478,500
Issued: November 19, 2019
Inventor(s): Querbes William & Fitzgerald Kevin & Bettencourt Brian & Liebow Abigail & Erbe David V.
Assignee(s): Alnylam Pharmaceuticals, Inc.The invention relates to RNAi agents, e.g. double-stranded RNAi agents, targeting the HAO1 gene, and method of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. Described herein are double-stranded RNAi agents which inhibit the expression of a HA01 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a HAO1 associated disorder, and uses of such double-stranded RNAi agents. In certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified.
Patent expiration dates:
- October 9, 2035✓✓✓
- October 9, 2035
-
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent 10,487,330
Issued: November 26, 2019
Inventor(s): Brown Bob D. & Dudek Henryk T.
Assignee(s): Dicerna Pharmaceuticals, Inc.This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Patent expiration dates:
- December 26, 2034✓✓✓
- December 26, 2034
-
Modified double-stranded RNA agents
Patent 10,612,024
Issued: April 7, 2020
Inventor(s): Maier Martin & Foster Don & Milstein Stuart & Kuchimanchi Satya & Jadhav Vasant & Rajeev Kallanthottathil & Manoharan Muthiah & Parmar Rubina
Assignee(s): ALNYLAM PHARMACEUTICALS, INC.One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2′-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
Patent expiration dates:
- August 14, 2035✓✓✓
- August 14, 2035
-
Modified double-stranded RNA agents
Patent 10,612,027
Issued: April 7, 2020
Inventor(s): Maier Martin & Foster Don & Milstein Stuart & Kuchimanchi Satya & Jadhav Vasant & Rajeev Kallanthottathil & Manoharan Muthiah & Parmar Rubina
Assignee(s): ALNYLAM PHARMACEUTICALS, INC.One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2′-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
Patent expiration dates:
- August 14, 2035✓✓✓
- August 14, 2035
-
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent 11,060,093
Issued: July 13, 2021
Inventor(s): Brown Bob D. & Dudek Henryk T.
Assignee(s): Dicerna Pharmaceuticals, Inc.This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Patent expiration dates:
- December 26, 2034✓✓✓
- December 26, 2034
-
Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Patent 11,261,447
Issued: March 1, 2022
Inventor(s): Erbe David V. & McGregor Tracy L.
Assignee(s): Alnylam Pharmaceuticals, Inc.The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.
Patent expiration dates:
- November 20, 2038✓✓✓
- November 20, 2038
-
Modified double-stranded RNA agents
Patent 11,401,517
Issued: August 2, 2022
Inventor(s): Maier; Martin et al.
Assignee(s): ALNYLAM PHARMACEUTICALS, INC. (Cambridge, MA)One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2′-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
Patent expiration dates:
- August 14, 2035✓✓✓
- August 14, 2035
-
Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Patent 11,446,380
Issued: September 20, 2022
Inventor(s): Querbes William & Fitzgerald Kevin & Bettencourt Brian & Liebow Abigail & Erbe David V.
Assignee(s): Alnylam Pharmaceuticals, Inc.The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.
Patent expiration dates:
- October 9, 2035✓✓
- October 9, 2035
-
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent 8,106,022
Issued: January 31, 2012
Inventor(s): Manoharan Muthiah & Rajeev Kallanthottathil G. & Narayanannair Jayaprakash K. & Maier Martin
Assignee(s): Alnylam Pharmaceuticals, Inc.The present invention provides iRNA agents comprising at least one subunit of the formula (I):
Patent expiration dates:
- December 12, 2029✓✓✓
- December 12, 2029
-
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent 8,828,956
Issued: September 9, 2014
Inventor(s): Manoharan Muthiah & Rajeev Kallanthottathil G. & Jayaprakash Narayanannair K. & Maier Martin
Assignee(s): Alnylam Pharmaceuticals, Inc.The present invention provides iRNA agents comprising at least one subunit of the formula (I):
Patent expiration dates:
- December 4, 2028✓✓✓
- December 4, 2028
-
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent 9,828,606
Issued: November 28, 2017
Inventor(s): Brown Bob D. & Dudek Henryk T.
Assignee(s): Dicerna Pharmaceuticals, Inc.This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Patent expiration dates:
- December 26, 2034✓✓
- December 26, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 6, 2025 - EXPANDED INDICATION TO INCLUDE LOWERING OF PLASMA OXALATE LEVELS IN ADULT AND PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
- November 23, 2025 - NEW CHEMICAL ENTITY
- November 23, 2027 - TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER URINARY OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
- October 6, 2029 - TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER PLASMA OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
More about Oxlumo (lumasiran)
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
